We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $133B
1-Year Est. Return 43.5%
This Fund
S&P 500
This Quarter Est. Return
+26.39%
1 Year Est. Return
+43.5%
3 Year Est. Return
+132.19%
5 Year Est. Return
+175.35%
10 Year Est. Return
+672.4%
AUM
$133B
AUM Growth
+$15.7B
Cap. Flow
-$1.75B
Cap. Flow %
-1.32%
Top 10 Hldgs %
30.35%
Holding
4,370
New
224
Increased
1,883
Reduced
1,827
Closed
182

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$212M
2
MSFT icon
Microsoft
MSFT
+$156M
3
AMZN icon
Amazon
AMZN
+$142M
4
HON icon
Honeywell
HON
+$119M
5
NVDA icon
NVIDIA
NVDA
+$94.5M

Sector Composition

Rank Sector Weight
1 Technology 35.1%
2 Financials 11.93%
3 Industrials 10.35%
4 Consumer Discretionary 9.64%
5 Healthcare 9.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
M icon
851
Macy's
M
$5.92B
$16.5M 0.01%
701,448
+5,300
+0.8% +$111K
AVTR icon
852
Avantor
AVTR
$10.3B
$16.5M 0.01%
1,668,123
+9,685
+0.6% +$83.4K
FND icon
853
Floor & Decor
FND
$4.87B
$16.5M 0.01%
277,729
-10,467
-4% -$530K
ARE icon
854
Alexandria Real Estate Equities
ARE
$8.3B
$16.5M 0.01%
311,729
-9,480
-3% -$454K
QRVO icon
855
Qorvo
QRVO
$10.3B
$16.5M 0.01%
176,442
-38,016
-18% -$3.51M
RYN icon
856
Rayonier
RYN
$5.54B
$16.4M 0.01%
769,318
-16,567
-2% -$347K
ACMR icon
857
ACM Research
ACMR
$5.21B
$16.4M 0.01%
128,979
-13,032
-9% -$921K
CORT icon
858
Corcept Therapeutics
CORT
$12.5B
$16.3M 0.01%
187,772
-2,926
-2% -$177K
SSNC icon
859
SS&C Technologies
SSNC
$18.3B
$16.3M 0.01%
262,842
-15,409
-6% -$1.05M
EMN icon
860
Eastman Chemical
EMN
$7.52B
$16.1M 0.01%
240,640
-53,128
-18% -$3.89M
MGM icon
861
MGM Resorts International
MGM
$8.13B
$16.1M 0.01%
336,151
-48,967
-13% -$2.04M
IREN icon
862
Iris Energy
IREN
$16.7B
$16.1M 0.01%
351,312
+302,740
+623% +$15.7M
MATX icon
863
Matsons
MATX
$6.66B
$16M 0.01%
83,388
-10,848
-12% -$1.98M
MSM icon
864
MSC Industrial Direct
MSM
$6.75B
$16M 0.01%
134,145
-4,331
-3% -$460K
RIVN icon
865
Rivian
RIVN
$21.6B
$15.9M 0.01%
914,538
-53,101
-5% -$828K
LGND icon
866
Ligand Pharmaceuticals
LGND
$6.14B
$15.8M 0.01%
50,125
-6,675
-12% -$1.57M
OZK icon
867
Bank OZK
OZK
$5.05B
$15.8M 0.01%
303,917
-21,542
-7% -$1.05M
SYNA icon
868
Synaptics
SYNA
$3.94B
$15.8M 0.01%
126,797
+2,777
+2% +$314K
UCTT
869
Ultra Clean Holdings
UCTT
$3.45B
$15.7M 0.01%
110,452
-17,251
-14% -$1.52M
SBRA icon
870
Sabra Healthcare REIT
SBRA
$5.03B
$15.7M 0.01%
806,867
+27,910
+4% +$554K
CBT icon
871
Cabot Corp
CBT
$4.03B
$15.7M 0.01%
173,187
+6,804
+4% +$556K
PTCT icon
872
PTC Therapeutics
PTCT
$5.39B
$15.7M 0.01%
192,706
-19,756
-9% -$1.43M
MRCY icon
873
Mercury Systems
MRCY
$4.89B
$15.6M 0.01%
127,926
-16,868
-12% -$1.61M
BLD
874
DELISTED
TopBuild
BLD
$15.6M 0.01%
44,088
-26,941
-38% -$11.1M
VSEC icon
875
VSE Corp
VSEC
$4.87B
$15.6M 0.01%
68,366
-6,271
-8% -$1.2M

Similar funds

RhumbLine Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, RhumbLine Advisers held 4,370 positions worth $133B, up 13% from $117B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

RhumbLine Advisers's Q2 2026 filing shows 224 new, 1,883 increased, 1,827 reduced and 182 closed positions. Its largest new stake was Honeywell Aerospace: 529,091 shares worth $117M. The largest sale was Apple, an estimated $212M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 31% a quarter earlier, followed by Financials and Industrials.

  • RhumbLine Advisers's largest Q2 2026 buy was Honeywell Aerospace: 529,091 shares worth $117M.
  • RhumbLine Advisers added most to Marvell Technology in Q2 2026, an estimated $117M increase.
  • RhumbLine Advisers's biggest Q2 2026 reduction was Apple, cutting an estimated $212M.
  • RhumbLine Advisers fully exited Coterra Energy in Q2 2026, selling an estimated $53.5M.
  • RhumbLine Advisers's ten largest holdings make up 30% of its $133B portfolio in Q2 2026.
  • RhumbLine Advisers opened 224 new positions and closed 182 in Q2 2026.
  • RhumbLine Advisers's portfolio value rose 13% quarter-over-quarter to $133B.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.